Stock GOSS GOSSAMER BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Real-time Estimate Cboe BZX
Other stock markets
 02:37:48 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.669 USD -0.15% Intraday chart for Gossamer Bio, Inc. -14.47% -26.53%
Mar. 13 Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM
Mar. 12 Gossamer Bio Announces Board of Directors Appointments CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
BU
Gossamer Bio Announces Board of Directors Appointments
CI
Goldman Sachs Adjusts Price Target on Gossamer Bio to $8 From $9, Maintains Buy Rating
MT
Gossamer Bio: Q4 Earnings Snapshot
AQ
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
BU
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
HC Wainwright Adjusts Price Target on Gossamer Bio to $10 From $5, Keeps Buy Rating
MT
Transcript : Gossamer Bio, Inc. - Special Call
Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from NASDAQ Biotechnology Index
CI
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
BU
Gossamer bio announces inducement grant under nasdaq listing rule 5635(4)
AQ
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
BU
Gossamer Bio Inc. Appoints Bob Smith as Chief Commercial Officer
CI
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
BU
Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors
CI
Wedbush Lifts Gossamer Bio's PT to $6 From $5, Increases Multiple for Seralutinib for Pulmonary Arterial Hypertension in US, EU; Keeps Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GOSS Stock
  4. News Gossamer Bio, Inc.